ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO138

Dicarboxylic Acid Supplementation Protects Mice From AKI via Increased Renal Peroxisomal Activity

Session Information

  • AKI: Mechanisms - II
    November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Silva Barbosa, Anne Caroline, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Pfister, Katherine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Chiba, Takuto, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Goetzman, Eric S., University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Sims-Lucas, Sunder, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Lysine succinylation is a posttranslational modification associated with the control of acute kidney injury (AKI). Hypersuccinylation favors peroxisomal fatty acid oxidation (FAO) instead of mitochondrial. In addition, the medium-chain fatty acids dodecanedioic acid (DC12) and octanedioic acid (DC8), upon FAO, originate succinyl-CoA, a succinylation co-factor.


To test the roles of medium-chain fatty acids during AKI, mice were fed with a control, a 10% w/w DC12, or 10% w/w DC8 diet, then, subjected to two models of AKI, unilateral renal ischemia-reperfusion (IRI), or an in-bolus cisplatin injection (20mg/kg). Supplementation was provided until sacrifice. Cisplatin animals were euthanized 3 days after injury, whereas IRI mice underwent contralateral nephrectomy on day 6 and were euthanized on day 7. Biochemical, histologic, genetic, and proteomic analyses were performed; the latter involving a lysine-succinylome-based mass spectrometry (LSMS).


DC12 prevented the rise of serum creatinine, blood urea nitrogen, and renal injury markers in mice during both models of AKI as well as improved morphology compared with controls. However, DC8 was even more protective against AKI than DC12. Intriguingly, while DC8 promotes succinylation in the kidneys only, DC12promotes it in both the liver and kidneys. Finally, LSMS evidenced that, regardless of surgical status, the kidneys of DC12- and DC8-fed mice showed, respectively, mild and extensive upregulation of a myriad of peroxisomal activity-related peptides, and a decline in mitochondrial FAO in comparison to control-fed mice.


DC8 or DC12 supplementation drives renal hypersuccinylation, promoting a shift from mitochondrial to peroxisomal fatty acid oxidation, and protecting against AKI. Dicarboxylic acid supplementation is convenient, inexpensive, easily administered, and efficient in preventing AKI. We believe this study could be translated in the future to the clinical setting, which would highly benefit the high-risk population.